McKesson Corporation vs Range Resources Corporation Common Stock — how do they compare? McKesson Corporation trades at $983.95 (market cap $112.15B), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: McKesson Corporation is far larger — about 11.3× Range Resources Corporation Common Stock's market cap, and Range Resources Corporation Common Stock pays the higher dividend (0.94%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Range Resources Corporation Common Stock for 0 Days on average.
| MCK | RRC | |
|---|---|---|
Market Cap | $112.15B | $9.93B |
Volume | 743,618 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $995.69 | $47.65 |
52-Week Low | $725.17 | $33.43 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $118.68B | $10.94B |
Dividend Yield | 0.39% | 0.94% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →